Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

858
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
858
Tumor Immunotherapy01:27

Tumor Immunotherapy

491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

686
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
686

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure of ergosteryl-aspartate synthase reveals how an entrapped tRNA is used like a prosthetic swinging arm in the synthesis of aminoacylated sterols.

Nature communications·2026
Same author

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Blood·2026
Same author

Preoperative lymphocyte signature predicts pancreatic fistula after pancreatoduodenectomy.

Communications medicine·2026
Same author

The Phylogenomic Approach Suggests That Butyrophilins Have Ligands Beyond Gamma-Delta Receptors.

International journal of molecular sciences·2026
Same author

Efferocytic remodelling of pancreatic islet macrophages by limited β-cell death.

Nature·2025
Same author

Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti-PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer.

Cancer immunology research·2025

Related Experiment Video

Updated: Jun 12, 2025

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.7K

Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis.

Anne-Charlotte Le Floch1, Caroline Imbert1, Nicolas Boucherit1

  • 1Centre de Recherche en Cancérologie de Marseille, INSERM U1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli Calmettes, Marseille, France.

Cancer Immunology Research
|September 20, 2024
PubMed
Summary

A new antibody targeting BTN2A1 significantly boosts Vγ9Vδ2 T-cell cancer-fighting abilities. This approach triggers pyroptosis, a form of cell death, offering potential for treating difficult "cold" tumors.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.9K

Related Experiment Videos

Last Updated: Jun 12, 2025

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.7K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.9K

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Vγ9Vδ2 T cells are crucial for anti-cancer immunity but their function is difficult to harness.
  • Butyrophilin subfamily 2 member A1 (BTN2A1) interacts with the γδ T-cell receptor, but its role in T-cell modulation is unclear.

Purpose of the Study:

  • To investigate the function of BTN2A1 in Vγ9Vδ2 T-cell responses.
  • To evaluate the therapeutic potential of a BTN2A1-agonist antibody (107G3B5) in cancer treatment.

Main Methods:

  • Utilized a monoclonal BTN2A1 agonist antibody (107G3B5).
  • Employed advanced computer vision and holotomographic microscopy to analyze T-cell interactions.
  • Assessed Vγ9Vδ2 T-cell activity against various cancer cell lines and primary patient cells.

Main Results:

  • 107G3B5 significantly enhanced Vγ9Vδ2 T-cell cytotoxicity against hematologic and solid tumors, including acute lymphoblastic leukemia.
  • Computer vision analysis revealed improved quantitative and qualitative interactions between T cells and target cells.
  • Activated Vγ9Vδ2 T cells induced caspase 3/7 activation, leading to pyroptosis and tumor cell death.

Conclusions:

  • Targeting BTN2A1 with 107G3B5 enhances Vγ9Vδ2 T-cell antitumor activity through pyroptosis-induced immunogenic cell death.
  • This pyroptosis-based strategy shows promise for cancer immunotherapy, particularly for 'cold' tumors resistant to conventional treatments.